Integrative Profiling Analysis Reveals Prognostic Significance, Molecular Characteristics, and Tumor Immunity of Angiogenesis-related Genes in Soft Tissue Sarcoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jun 28

PMID 37377953

Authors

Binfeng Liu

Chenbei Li

Chengyao Feng

Hua Wang

Haixia Zhang

Chao Tu

Shasha He

Zhihong Li

Affiliations

Soon will be listed here.

Abstract

Background: Soft tissue sarcoma (STS) is a class of malignant tumors originating from mesenchymal stroma with a poor prognosis. Accumulating evidence has proved that angiogenesis is an essential hallmark of tumors. Nevertheless, there is a paucity of comprehensive research exploring the association of angiogenesis-related genes (ARGs) with STS.

Methods: The ARGs were extracted from previous literature, and the differentially expressed ARGs were screened for subsequent analysis. Next, the least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were conducted to establish the angiogenesis-related signature (ARSig). The predictive performance of the novel ARSig was confirmed using internal and external validation, subgroup survival, and independent analysis. Additionally, the association of the ARSig with the tumor immune microenvironment, tumor mutational burden (TMB), and therapeutic response in STS were further investigated. Notably, we finally conducted experiments to verify the findings from the bioinformatics analysis.

Results: A novel ARSig is successfully constructed and validated. The STS with a lower ARSig risk score in the training cohort has an improved prognosis. Also, consistent results were observed in the internal and external cohorts. The receiver operating characteristic (ROC) curve, subgroup survival, and independent analysis further indicate that the novel ARSig is a promising independent prognostic predictor for STS. Furthermore, it is proved that the novel ARSig is relevant to the immune landscape, TMB, immunotherapy, and chemotherapy sensitivity in STS. Encouragingly, we also validate that the signature ARGs are significantly dysregulated in STS, and ARDB2 and SRPK1 are closely connected with the malignant progress of STS cells.

Conclusion: In sum, we construct a novel ARSig for STS, which could act as a promising prognostic factor for STS and give a strategy for future clinical decisions, immune landscape, and personalized treatment of STS.

References

Blay J, Ray-Coquard I . Sarcoma in 2016: Evolving biological understanding and treatment of sarcomas. Nat Rev Clin Oncol. 2016; 14(2):78-80. DOI: 10.1038/nrclinonc.2016.200. View

Swanton C . Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012; 72(19):4875-82. PMC: 3712191. DOI: 10.1158/0008-5472.CAN-12-2217. View

Ash D, Sudhahar V, Youn S, Okur M, Das A, OBryan J . The P-type ATPase transporter ATP7A promotes angiogenesis by limiting autophagic degradation of VEGFR2. Nat Commun. 2021; 12(1):3091. PMC: 8149886. DOI: 10.1038/s41467-021-23408-1. View

Aung T, Asam C, Haerteis S . Ion channels in sarcoma: pathophysiology and treatment options. Pflugers Arch. 2019; 471(9):1163-1171. DOI: 10.1007/s00424-019-02299-8. View

Li Y, Yu S, Wang X, Ye X, He B, Quan M . SRPK1 facilitates tumor cell growth via modulating the small nucleolar RNA expression in gastric cancer. J Cell Physiol. 2019; 234(8):13582-13591. DOI: 10.1002/jcp.28036. View

Geeleher P, Cox N, Huang R . pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014; 9(9):e107468. PMC: 4167990. DOI: 10.1371/journal.pone.0107468. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Charfi C, Levros Jr L, Edouard E, Rassart E . Characterization and identification of PARM-1 as a new potential oncogene. Mol Cancer. 2013; 12:84. PMC: 3750824. DOI: 10.1186/1476-4598-12-84. View

Chang L, Asatrian G, Dry S, James A . Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2014; 32(1):430. DOI: 10.1007/s12032-014-0430-9. View

10.

Cheng D, Li J, Li S, Yang Q, Fan C . CNOT1 cooperates with LMNA to aggravate osteosarcoma tumorigenesis through the Hedgehog signaling pathway. Mol Oncol. 2017; 11(4):388-404. PMC: 5527480. DOI: 10.1002/1878-0261.12043. View

11.

Pages F, Galon J, Dieu-Nosjean M, Tartour E, Sautes-Fridman C, Fridman W . Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2009; 29(8):1093-102. DOI: 10.1038/onc.2009.416. View

12.

Zheng M, Liu J, Bian T, Liu L, Sun H, Zhou H . Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma. Int Immunopharmacol. 2020; 90:107134. DOI: 10.1016/j.intimp.2020.107134. View

13.

Gammons M, Lucas R, Dean R, Coupland S, Oltean S, Bates D . Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014; 111(3):477-85. PMC: 4119992. DOI: 10.1038/bjc.2014.342. View

14.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

15.

Gras Navarro A, Espedal H, Joseph J, Trachsel-Moncho L, Bahador M, Gjertsen B . Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers (Basel). 2019; 11(7). PMC: 6678126. DOI: 10.3390/cancers11070996. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Wang Z, Cao L, Zhou S, Lyu J, Gao Y, Yang R . Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration. Front Immunol. 2022; 13:854785. PMC: 8980360. DOI: 10.3389/fimmu.2022.854785. View

18.

Choi J, Ro J . The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol. 2020; 28(1):44-58. DOI: 10.1097/PAP.0000000000000284. View

19.

Chen G, Luo D, Zhong N, Li D, Zheng J, Liao H . GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. Front Immunol. 2022; 13:857308. PMC: 8957202. DOI: 10.3389/fimmu.2022.857308. View

20.

Shashni B, Nishikawa Y, Nagasaki Y . Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles. Biomaterials. 2021; 269:120645. DOI: 10.1016/j.biomaterials.2020.120645. View